Keryx Biopharmaceuticals, Inc. (the “Company”) today announced that an article entitled “Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom’s Macroglobulinemia,” reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom’s Macroglobulinemia (“Waldenstrom’s”), will appear in the February 1, 2010 issue of Clinical Cancer Research. Continue Reading
Bill and Melinda Gates announced today that their foundation will commit $10 billion over the next 10 years to help research, develop and deliver vaccines for the world’s poorest countries. Continue Reading
New guidance published in the open access journal Trials and bmj.com this week sets out how personal information from clinical trials should be shared to help minimize risks to patient privacy. Continue Reading
Safe food attorney Bill Marler has called for the USDA’s Food Safety and Inspection Service (FSIS) to label meats that have undergone mechanical tenderization. The controversial process has been linked to numerous outbreaks of the dangerous pathogen E. coli O157:H7, yet there is currently no disclosure required. Continue Reading
Beech Tree Labs, Inc., announced today that the FDA has approved its IND for a 180 patient Phase 1/2a clinical evaluation of BTL-TML001, a novel therapeutic agent for treating acute influenza virus infections. Continue Reading
Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy. Continue Reading
Omeros Corporation today announced that the National Institute on Drug Abuse (NIDA) is providing support for the Company’s Addiction program. NIDA will fund substantially all of the costs of a Phase 2 clinical study to be conducted by New York State Psychiatric Institute researchers. Continue Reading
Dr. Harry Ostrer, professor of pediatrics, pathology and medicine at NYU Langone Medical Center will be conducting genetic screening at four college campuses in Boston on February 1st and 2nd. Individuals interested in being screened should sign- up online at www.med.nyu.edu/genetics. Continue Reading
Scientists have long pondered the seeming contradiction that taking broad-spectrum antibiotics over a long period of time can lead to severe secondary bacterial infections. Now researchers from the University of Pennsylvania School of Medicine may have figured out why. Continue Reading
With the help of effective drug therapies, HIV patients are living longer, healthier lives. Now, researchers want to improve these drug therapies and develop alternative preventative strategies, such as vaginal gels and creams that contain the same or related compounds used in treatments for people infected with HIV. Continue Reading
